Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Baxter International Inc (BAX) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 25,145,420
  • Shares Outstanding, K 543,890
  • Annual Sales, $ 9,968 M
  • Annual Income, $ 968 M
  • 36-Month Beta 0.82
  • Price/Sales 2.48
  • Price/Book 2.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.95 +4.71%
on 12/28/16
47.40 -2.91%
on 01/20/17
+1.80 (+4.07%)
since 12/23/16
3-Month
43.13 +6.70%
on 12/07/16
50.16 -8.25%
on 10/25/16
-2.16 (-4.48%)
since 10/21/16
52-Week
35.42 +29.93%
on 01/28/16
50.16 -8.25%
on 10/25/16
+9.95 (+27.59%)
since 01/22/16

Most Recent Stories

More News
Vial Adaptors for Reconstitution Drug Market to be Worth US$1.3 Billion by 2024: Reduced Risk of Needlestick Injuries Ups Demand, Notes TMR

ALBANY, New York, January 19, 2017 /PRNewswire/ --

Vial Adaptors for Reconstitution Drug Market to be Worth US$1.3 Billion by 2024: Reduced Risk of Needlestick Injuries Ups Demand, Notes TMR

The Global Vial Adaptor for Reconstitution Drug Market is fairly consolidated as top four players hold a leading share in the global market. A report by Transparency Market Research states that West Pharmaceutical...

Spectrum Health Recognized for Excellence in Community Service with 2016 Foster G. McGaw Prize

In recognition of its cutting-edge programs and services to reach the underserved residents of Western Michigan, Spectrum Health is awarded the 2016 Foster G. McGaw Prize for Excellence in...

Baxter (BAX): Sluggish Macro Environment Mars Prospects

On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

Blog Coverage Teleflex's Arrow(R) VPS Rhythm(TM) Device gets FDA Clearance; Launches Laryngeal Mask

Upcoming AWS Coverage on Baxter International Post-Earnings Results

Robins Kaplan LLP Appointed Co-Lead Counsel in Class Action Antitrust Lawsuit Alleging Collusion Among Suppliers of Saline to U.S. Hospitals

National trial firm Robins Kaplan LLP(R) announced today that it has been appointed co-lead counsel in a class action antitrust lawsuit against the three dominant suppliers of IV saline solution,...

Is Baxter Poised to Counter Low Cyclophosphamide Sales?

On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

Boston Scientific Down on Risks; Innovations Raise Hope

On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

Qiagen Poised on Fundamentals, Expansion Plans on Track

On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).

Myriad Genetics: United Rheumatology Selects Vectra DA Test

Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience's Vectra DA assay has been added by United Rheumatology to its clinical practice guidelines for adults with rheumatoid arthritis.

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Weakening.

See More

Business Summary

Baxter engages in the worldwide development, manufacture and distribution of a diversified line of products, systems and services used primarily in the health-care field. The company's products are used by hospitals, clinical and medical research laboratories, blood and dialysis centers, rehabilitation...

See More

Support & Resistance

2nd Resistance Point 46.76
1st Resistance Point 46.39
Last Price 46.02
1st Support Level 45.65
2nd Support Level 45.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.